Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era
Introduction The Omicron BA.1 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and subsequent sub-lineages exhibit partial escape from neutralizing antibodies elicited by vaccines containing or encoding wild-type spike protein. In response to the emergence of Omicron sub-linea...
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Taylor & Francis Group
2023-12-01
|
| Edice: | Expert Review of Vaccines |
| Témata: | |
| On-line přístup: | http://dx.doi.org/10.1080/14760584.2023.2232851 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|